| Crop | Region/indoora | Residue levels observed in the supervised residue trials relevant to the supported GAPs (mg/kg) | Recommendations/comments (OECD calculations) | MRL proposals(mg/kg) | HRMo (mg/kg)b | STMRMo (mg/kg)c | CFd |
|---|---|---|---|---|---|---|---|
| Genetically modified GAT cropsRD‐enforcement 1 = RD‐enforcement 2: sum of glyphosate, AMPA and N‐acetyl‐glyphosate, expressed as glyphosate | |||||||
| Rapeseeds | Import (US) |
Mo: 1.83; 10.1; 5.6; 1.58; 2.8; 3.3; 5.8; 11.2; 3.5; 2.7; 3.3; 2.2; 0.88; 0.81; 14.8 RA: 1.88; 10.2; 5.6; 1.63; 2.9; 3.4; 5.8; 11.2; 3.5; 2.7; 3.3; 2.3; 0.93; 0.86; 15.2 |
GAT GM rapeseed is currently not authorised for placing on the market within the EU. Therefore, GAP and supporting residue trials were not considered further in the assessment. MRLOECD = 21.34 |
– | – | – | – |
GAP: Good Agricultural Practice; OECD: Organisation for Economic Co‐operation and Development; MRL: maximum residue level.
NEU: Outdoor trials conducted in northern Europe, SEU: Outdoor trials conducted in southern Europe, Indoor: indoor EU trials or Country code: if non‐EU trials.
Highest residue according to the residue definition for monitoring.
Supervised trials median residue according to the residue definition for monitoring.
Conversion factor for risk assessment; median of the individual conversion factors at the supported PHI for each residues trial.